METADATA
last updated: 2026-03-06 by BA
file_name: BARDA Market Research - FloodLAMP Presentation (2022-03-07).md
file_date: 2022-03-07
title: BARDA Market Research - FloodLAMP Presentation (2022-03-07)
category: various
subcategory: fl-presentations
tags:
source_file_type: gslide
xfile_type: pptx
gfile_url: https://docs.google.com/presentation/d/1lv_tXtw7Q8OPwji6TB_aq1aPFF-616rdeIvVkBWr_AM
xfile_github_download_url: https://raw.githubusercontent.com/FocusOnFoundationsNonprofit/floodlamp-archive-wip/main/various/fl-presentations/BARDA%20Market%20Research%20-%20FloodLAMP%20Presentation%20%282022-03-07%29.pptx
pdf_gdrive_url: https://drive.google.com/file/d/1Sp3L8CDqbgKZSwP5pnEArSbJWVted2MY
pdf_github_url: https://github.com/FocusOnFoundationsNonprofit/floodlamp-archive-wip/blob/main/various/fl-presentations/BARDA%20Market%20Research%20-%20FloodLAMP%20Presentation%20%282022-03-07%29.pdf
conversion_input_file_type: pdf
conversion: megaparse
license: CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/
tokens: 12077
words: 6626
notes:
summary_short: The “Extending the Reach of LAMP” BARDA market research deck (March 7, 2022) presents FloodLAMP’s case for a globally accessible, decentralized molecular screening platform built around pooled collection, an instrument-free QuickColor LAMP assay paired with a sister PCR assay, and wraparound digital, training, and quality systems. It summarizes real-world municipal/EMS and school pilots, argues for “open EUA” regulatory pathways with full component disclosure to enable interoperable “generic” diagnostics, and outlines the operational assets (kits, portable lab setups, mobile app/admin portal) needed to scale rapid community screening.


CONTENT

## Slide 1: FloodLAMP Biotechnologies, PBC
Extending the Reach of LAMP: A platform for globally accessible disease screening

BARDA Market Research = March 7, 2022
Randy True, Founder and CEO | randy@floodlamp.bio


## Slide 2: FloodLAMP's Mission
**FloodLAMP's mission is to improve global health and resiliency through universal access to rapid molecular testing.**
1. New testing technology
2. Turnkey screening programs
3. Disruptive open source strategy


## Slide 3: 2) Platform - Wraparound program components
_Diagram grid summarizing the FloodLAMP platform—applications across diseases, core modules split into physical and digital components, product offerings, and network partner groups._

### Applications
- COVID Response
- Emerging Threats (Pandemic Prep)
- TB / Zikka
- Influenza / STD’s / Cancer

### Core Modules
#### Physical
- Reagent Test Kits
- Collection Kits
- Standard Consumables
- Standard Equipment

#### Digital
- App
- Admin Portal
- Training Program
- Quality Management System

### Network
- EMS & Municipalities
- Schools and Businesses
- U.S. Federal Agencies (BARDA, ASPR, CDC, DoD, FEMA)
- International Governments

### Products
- All-in Test Kits
- Sample Processing Sites (Labs)
- Service, Support, Consulting
- Testing Program Management


## Slide 4: PCR and LAMP Sister Assays
### Streamlined Sample Prep
_Drawing of 4 swabs in tubes being eluted_
- Shelf stable TCEP/EDTA inactivation solution
- Added directly to dry swabs

- Same sample for both tests
- 2µL sample volume

### QuickColor(TM) LAMP Test
_Drawing on 6 reaction tubes with the first one showing a yellow positive LAMP reaction and the other 5 pink for negative_
- Colorimetric LAMP reaction
- 3 primer sets mixed (AS1e, N2, E1)
- 25 minutes at 65°C

### EasyPCR(TM) Test
_Drawing of a PCR machine_
- Multiple PCR Master Mixes Validated
- CDC primers in SalivaDirect config (N1, RNAseP)


## Slide 5: The Performance Sweet Spot
_Diagram (Venn-style) contrasting rapid turnaround, low cost, and good sensitivity, with FloodLAMP positioned as the “sweet spot” relative to antigen strips, rapid cartridges, and clinical lab PCR._
```mermaid
flowchart TB

  %% Core performance pillars (circle-shaped)
  RT((Rapid Turnaround Time<br/>&lt; 2 hrs sample to answer))
  LC((Low Cost<br/>&lt; $5 per person))
  GS((Good Sensitivity<br/>Detects Pre-Infectious Asymptomatics))

  %% Modalities (placed in their Venn regions via connections) - circle-shaped
  antigen((Antigen Test Strips))
  cartridges((Rapid Molecular Cartridges))
  labPCR((Clinical Lab Purified PCR))

  %% Center labels (IMPORTANT: separated like the slide) - circle-shaped
  quickcolor((FloodLAMP<br/>QuickColor™))
  saliva((SalivaDirect™ &<br/>FloodLAMP Pooled<br/>Swab PCR))

  %% Overlaps / region membership (structural logic)
  RT --- antigen
  LC --- antigen

  RT --- cartridges
  GS --- cartridges

  %% Clinical lab PCR is only in Good Sensitivity (not low cost / not rapid)
  GS --- labPCR

  %% True center overlap (all three)
  RT --- quickcolor
  LC --- quickcolor
  GS --- quickcolor

  %% Lower overlap label (Low Cost + Good Sensitivity only)
  LC --- saliva
  GS --- saliva

  %% Side notes / callouts
  note_conf["People want higher confidence<br/>for both positive and negative results."]
  note_capex["High upfront capital cost for PCR instruments limit replicability. These 2<br/>tests have potential to drive down PCR costs."]
  note_turn["Long turnaround renders it unsuitable for large scale screening<br/>- schools and workplaces need to know quickly if someone is infected."]
  note_conc["Will help usher in era of at-home concierge diagnostics but simply too<br/>constrained by manufacturing and too expensive for public health screening."]

  %% Benefits box (blue in slide)
  benefits["• Improved performance<br/>• Good sensitivity<br/>• Fast turnaround<br/>• Cheap<br/>• Molecular<br/>• Flexible<br/>• Decentralised<br/>• Resilient"]

  %% Dashed callout connectors (match slide targets)
  note_conf -.- antigen
  note_capex -.- saliva
  note_turn -.- labPCR
  note_conc -.- cartridges

  %% Blue dashed connector in slide originates from the center QuickColor to the benefits box
  quickcolor -.- benefits
```


## Slide 6: Addressing Current Vulnerabilities
1. Antigen Tests are at Risk of Failure with New Variants

2. Multi-Gene Molecular Tests are Resilient to New Variants
- Test combines primer sets for 3 genes
  - ORF1ab ; N2 ; E1

- LAMP uses 6 primers and is highly tolerant to mismatches
  - (see recent NEB preprint analyzing our primers)

3. Reagent Based Molecular Tests are Adaptable and Scalable
- Primers swapped quickly and cheaply.
  - Other test components remain the same. 

- Primers produced in large volumes and distributed quickly.
  - 10s of M of reactions / production run.

4. FloodLAMP can deliver Prepositioned Assets
- For rapid response, scaling & surge capability
- Our systems comprise of ordinary, low-cost lab equipment
  - Offering best-in-class capacity per cost
- We deliver custom-designed wraparound components
  - E.g: digital tools, QA, training


## Slide 7: Operating Programs in the Real World
### ✅ EMS Leadership Conference Screening
- 1,000 attendees

### ✅ Municipal & EMS Deployments
- Coral Springs, FL (approx. 132,000)
- Davie, FL (approx. 104,000)
- Bend, OR (approx. 94,000)

### ✅ Preschool Screening with Family Pooling
- Approx. 40 families
- 65-105 people per bi-weekly screening

**FloodLAMP Surveillance Testing Stats (Thru Mar 2, 2022)**

| Org | Pools | People | Positives |
|---|---:|---:|---:|
| FL FF | 1,107 | 1,779 | 44 |
| FL FTFC | 61 | 195 | 0 |
| Kent Summer Camp | 190 | 696 | 0 |
| Coral Springs City | 7,400 | 21,676 | 348 |
| Davie Fire Rescue | 2,235 | 4,226 | 55 |
| Pink Shoes Production | 671 | 671 | 1 |
| Bend Fire Rescue | 617 | 617 | 215 |
| **TOTAL** | **12,281** | **29,860** | **663** |
||


## Slide 8: FloodLAMP's successful response to surges
Town of Davie, FL
_Bar chart collage showing weekly screening volumes and positive results/positivity during the Omicron surge, with peaks in early 2022._

Coral Springs, FL
_Bar chart collage showing weekly screening volumes and positive results/positivity during the Omicron surge, with peaks in early 2022._


## Slide 9: FloodLAMP's successful response to surges
Bend, OR
_Bar chart plotting week starting date (x-axis) versus number of people (y-axis), showing people screened with positives overlaid (percent positive labeled)_

Preschool, CA
_Bar chart plotting week starting date (x-axis) versus number of people (y-axis), showing people screened with positives overlaid (percent positive labeled)_


## Slide 10: Case Report: Pre-School Screening
- Several infections detected by FloodLAMP 1-2 days before symptoms or antigen tests
- In 3 different cases, family members of the preschool student were detected, showing the advantage of family pooling in protecting spread in a congregate setting such as schools and workplaces.

| Person/Test | 1/2/22 (Day 0) | 1/3/22 (Day 1) | 1/4/22 (Day 2) | 1/6/22 (Day 4) | 1/7/22 (Day 5) | 1/8/22 (Day 6) | 1/9/22 (Day 7) | 1/10/22 (Day 8) | 1/13/22 (Day 11) | 1/14/22 (Day 12) | 1/17/22 (Day 15) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Family Pool | POS FloodLAMP |  |  |  |  |  |  |  |  |  | POS FloodLAMP |
| Parent 1 | Asymptomatic<br>POS FloodLAMP (Family Pool)<br>NEG Antigen | POS FloodLAMP (Indiv) | POS PCR Lab (sent) |  | POS PCR Result |  | POS FloodLAMP (Indiv) | POS FL Result |  | NEG Antigen | POS FloodLAMP (Family Pool) |
| Parent 2 | Asymptomatic<br>POS FloodLAMP (Family Pool)<br>NEG Antigen | POS FloodLAMP<br>POS PCR Lab (sent) | Symptoms<br>POS PCR Result |  |  |  | POS FloodLAMP (Indiv) | POS FL Result |  | NEG Antigen | POS FloodLAMP (Family Pool) |
| Child 1 | Asymptomatic<br>POS FloodLAMP (Family Pool) | NEG FloodLAMP | Symptoms<br>POS Antigen | Asymptomatic | POS PCR Lab (sent) | POS PCR Result | POS FloodLAMP (Indiv) | POS FL Result |  | NEG Antigen | POS FloodLAMP (Family Pool) |
| Child 2 | Asymptomatic<br>POS FloodLAMP (Family Pool) | NEG FloodLAMP | Symptoms<br>POS Antigen | Asymptomatic<br>POS PCR Lab (sent) | POS PCR Result |  | POS FloodLAMP (Indiv) | POS FL Result | POS Antigen (slight) | NEG Antigen | POS FloodLAMP (Family Pool) |
||


## Slide 11: Case Report: New Year's Eve
Detection of an asymptomatic infection that was missed by 3 expensive OTC/POC rapid molecular tests 
- Detect, Lucira, Mesa Accula were negative
- BinaxNOW wasn't positive until 2 days later.
- All FloodLAMP positive samples confirmed by PCR

| Test | 12-27-21 | 12-29-21 | 12-31-21 | 12-31-22 | 1-1-22 | 1-2-22 |
|---|---|---|---|---|---|---|
| FloodLAMP EasyPCR on saliva |  |  |  | POS - SalivaDirect<br>PCR Ct 27.7<br>8 PM | POS - SalivaDirect<br>PCR Ct 29.0<br>11 AM |  |
| Accula Rapid Molecular PCR (Worksite) |  |  |  |  | Accula<br>NEG - nasal swab<br>4 PM |  |
| Lucira Rapid Molecular LAMP |  |  |  | Lucira<br>NEG - nasal swab<br>5 PM |  |  |
| Detect Rapid Molecular LAMP | NEG - nasal swab<br>10 AM |  | Detect<br>NEG - nasal swab<br>2 PM |  |  |  |
| CaseStart Antigen |  |  |  |  |  |  |
| FlowFlex Antigen |  | NEG - nasal swab<br>8 AM | NEG - nasal swab<br>2 PM |  |  | POS - nasal swab<br>10 AM |
| BinaxNow Antigen |  |  |  | NEG - nasal swab<br>5 PM | NEG - nasal and throat swabs<br>10 AM | POS - nasal swab<br>10 AM |
| FloodLAMP QuickColor LAMP Nasal Swab |  | NEG - nasal swab<br>1 PM |  | NEG - nasal swab<br>PCR Ct Und/39.4<br>5PM | POS - nasal swab<br>PCR Ct 32.2<br>10 AM |  |
| FloodLAMP QuickColor LAMP Throat Swab |  |  | POS - nasal swab<br>PCR Ct 33.9<br>9 AM | POS - throat swab<br>PCR Ct 30.2<br>5 PM | POS - throat swab<br>PCR Ct 35.5<br>10 AM |  |
||


## Slide 12: Open EUAS
- Provide a path to establishing generics in diagnostics (direct opposition to typical IVD EUA).
- FloodLAMP has submitted 2 Full EUAS + pre-EUA as open protocol.

| Question | Typical IVD EUA | CDC EUA | SalivaDirect™ | SHIELD | FloodLAMP EasyPCR™ | FloodLAMP QuickColor™ |
|---|---|---|---|---|---|---|
| Disclosure of all chemicals and reagents? | No | Yes | Yes | Yes | Yes | Yes |
| Chemical and reagents available from multiple vendors? | No | Yes | Yes | No | Yes | Yes |
| Disclosure of primer sequences? | No | Yes (std for PCR) | Yes | No (Proprietary Thermo) | Yes | Yes |
| Primers commercially available from multiple vendors? | No | Yes | Yes (CDC Primers) | No (Proprietary Thermo) | Yes (CDC SD Primers) | Yes (Available but not launched) |
| Supply chain robust? | No | No/Maybe | Yes | No/Maybe | Yes | Yes |
| EUA Sponsor Organization Type | For Profit Company | Govt | Academic Not for Profit | Academic Not/For Profit ? | Public Benefit Corp | Public Benefit Corp |
| Designation of CLIA labs | Kit Sales | N/A open RoR | Impact & Expansion | Impact & Expansion | Impact & Expansion | Impact & Expansion |
||


## Slide 13: Support for Further Implementation
Federal support is required for rapid deployment to both a number of interested organizations
(e.g. EMS, early child-care hospitals) and to the communities most in need.

### Rapid Response Surge Screening
- Immediately deployable to hotspots
- Highly replicable with low capital cost (unlike most PCR based mobile testing)
- Partner with local community groups for building trust and driving adoption

### Sustained Community Assurance Screening
- Anchored in schools and workplaces
- Expand to entire communities with flexible and convenient options
- Marry with policies such as test-to-stay that drive adoption

### Multi-Site Study
Compare to antigen studies on key endpoints:
- Additional reduction in Rt from Screening Program
- % participation in program 
- Participant satisfaction in program
- School/work days saved by program (test-to-stay)

### Network of EMS Surveillance Screening Sites
High need for screening critical first-responders  owing to the large degree of  vaccine hesitancy in this population
- FloodLAMP has established relationships with EMS leadership (facilitates rapid expansion)
- Ideal group to expand screening to schools and businesses (EMS has community trust)


## Slide 14: FloodLAMP Team
#### Randy True
Founder & CEO
Founder TMI Inc. Acq. Affymetrix
Former VP of R&D at. Affymetrix
bit.ly/biosketch-randalltrue
co-author global LAMP consortium review: bit.ly/GLAMP-review.
https://abrf.memberclicks.net/ibt-2021-september-issue

#### Theresa Ling
UX/Design Lead

#### Gary Withey, Ph.D.  
Vice President of Research & Development

#### Dr. Peter Antevy, MD
Program Medical Director 

#### Brandon Smith
Lab Assistant

### Scientific Advisory Board
Anne Wyllie
Yale, Lead Researcher SalivaDirect

Bill Hyun
UC San Francisco, Genoa Ventures

### Industry Advisors
Tim Lugo
William Blair Biotechnology Group Head

Zarak Khurshid
Asymmetry Capital, Top MDx Analyst

John Edge
Oxford Internet Institute, Blue Field Labs, ID2020

### Acknowledgments
Antanas Sadunas, Sam Fogelberg, Carey Tan,
Esmé Thornhill-Davis, Jeff Huber, Cliff Wang,
Chris Mason, Simon Johnson, Brett Johnson,
Mike Finney, Ron Cook
NSVD: Vincent Law, Michael Wells, Katrina
Brandis, Gaby Hartley, Tim Earley, Nasreen Haque
Research-Aid Networks: Jeremy Rossman
EMS deployments: Adam, Danny, Alex, Petar, Dr.
Paul Pepe
Thanks too to all of our advisors, volunteers &
former employees!


## Slide 15: APPENDIX
_Presentation Section Separator Slide_


## Slide 16: Quad Chart
### Upper Left Quadrant
#### Objective:
FloodLAMP's mission is to improve global health and resiliency through universal access to rapid molecular testing. We have developed a key capability that can help realize the enormous potential of the field of diagnostics in ending this pandemic, preparing for the next one, and improving human health globally. Our near term objective is to deploy hundreds of sites delivering easy to use, flexible, fast turnaround COVID surveillance screening to drive durable adoption in the communities most in need. 

#### Description of effort:
- Fully integrated turnkey surveillance programs comprising all equipment, consumables, test kits, pooled collection kits, digital tools, training, and support;
- Systems cost of $2K gives 20K/day capacity, at low cost of <$2 pp (incl labor);
- Currently 8 systems deployed with EMS departments in 3 states, 11 staff trained to run test (5 with no experience), 5,600 people screened, 36 unknown positive cases detected, 44 known confirmed (100%), no known FN;
- Full FDA EUAs submitted for 2 tests, duplex PCR and colorimetric LAMP, as open source protocol EUAs, clinical evaluation by Stanford CLIA lab with 98% (PCR) and 90% (LAMP) sensitivity, and 100% specificity, pre-EUA sub for pooled home collection w/ FloodLAMP Mobile App, IRB approved.
- Key advisors, collaborators and industry connections (Anne Wyllie of SalivaDirect, Robby Sikka's Sports & Society call, gLAMP consortium, NEB, LGC)

### Lower Left Quadrant
#### Benefits:
- Scalable and replicable high quality molecular screening, deployable anywhere;
- Rapid response to hot spots: 10K/day capacity bringup in 24hrs;
- Outbreak risk reduction and disease suppression in high-need communities;
- Acceleration of return-to-normal and economic activity;
- Increased adoption over DIY antigen tests through convenience to end user;
- Improved mitigation effectiveness of pooling at the family/household level;
- Establishment of critical new regulatory paradigm – the generics of diagnostics through open source protocol FDA authorized tests, LAMP primer standards, and point-of-need flexible public health testing.

#### Challenges:
- Regulatory barriers – access to FDA review as a startup;
- Supply chain and staffing;
- Educating the public and political leaders of the benefits of frequent screening.

#### Maturity of Technology:
- Demonstrated real world success of full programs at multiple sites;
- Test system clinical evaluation successful and FDA EUA validations completed;
- Patent filings and licenses in place to secure control of key IP; 
- Pilot manufacturing of test reagents (40K reactions/day);
- Reagent supply partners in place (LGC Biosearch and New England Biolabs);
- Quality system and training program in development.

### Upper Right Quadrant
#### FloodLAMP Mobile App:
- At home collection of family pools;
- Lightweight LIMS for tracking and reporting;
- Admin for mgmt, results, and metrics.
_Screenshot of the FloodLAMP Mobile App interface used for at-home family pool collection, tracking, and reporting._

#### QuickColor(TM) COVID-19 Test and Turnkey Screening Program:
- Instrument free rapid molecular test,
- 2 hrs to setup and validate site,
- 10K+/day throughput at <$5K cost.
_Photo of a QuickColor™ testing setup showing reaction tubes/plate and simple lab supplies for an instrument-free rapid molecular screening workflow._

### Lower Right Quadrant
#### Major Milestones:
##### Milestone 1 - State level contract for all EMS sites screening first responders:
- Hub and spoke model for smaller departments;
- Pilot expansion to under served communities, schools and workplaces.

##### Milestone 2 - FDA open source protocol EUAs for pooled direct LAMP and PCR:
- Complete asymptomatic clinical trial with enrichment strategy;
- EUA for DTC pooled collection kit using FloodLAMP Mobile App;
- Quality and training systems completed;
- U.S. FDA EUA enables global distribution and copy cats.

##### Milestone 3 - Full suite of open source resources:
- Modern website with all information, tools, products for various scales;
- Includes quality and training systems.

##### Milestone 4 - 5M tests deployed:
- Key reagents are in-hand, ready to kit and distribute.

#### Proposed Funding:
- Phase 0: 1 week – deep dive due diligence;
- Phase 1: 2-4 weeks – workplan incl Milestone 1 and TBD based on feedback;
- Phase 2: 2-6 weeks – workplan incl Milestones 1, 2, 3  and TBD based on feedback.


## Slide 17: Filling a Gap in the Testing Landscape
At Home OTC -> Point of Care -> Point of Need -> CLIA Labs

Current testing paradigms cannot stem a pandemic caused by an asymptomatically transmitted, aerosolized pathogen.

- Scaling a single test up to very high levels offers opportunities for innovation in sampling, test chemistry, and program configuration.
- A "Point of Need" modality of testing is needed that combines the scalability and low cost of liquid reagent processing with the ease, flexibility and decentralized nature of POC/At-Home.
- Public Health processing sites can fill the gap between CLIA labs and DIY at home tests.
- Want this new capability to be additive and not cannibalize the clinical diagnostic infrastructure.


## Slide 18: Open EUA's-2 Full Submissions + Pre EUA
_Screenshots of three document cover pages representing regulatory materials: QuickColor™ and EasyPCR™ COVID-19 test “Instructions for Use” plus a pooled swab collection kit document._
### FloodLAMP QuickColor(TM) COVID-19 Test
Instructions for Use v1.2
IVD
COVID-19 Emergency Use Authorization Only
For in vitro diagnostic (IVD) Use

### FloodLAMP EasyPCR(TM) COVID-19 Test
Instructions for Use v1.1
IVD
COVID-19 Emergency Use Authorization Only
For in vitro diagnostic (IVD) Use

FloodLAMP
Biotechnologies
A Public Benefit Corporation

### FloodLAMP Pooled Swab Collection Kit DTC
For use with the FloodLAMP Mobile App
www.floodlamp.bio
FloodLAMP Biotechnologies, PBC 930 Brittan Ave. San Carlos, CA 94070 USA


## Slide 19: Open EUA - Disclosure of Components
_Table collage showing disclosed Open EUA components: validated reagent list, primer names/sequences, and preparation tables for primer–guanidine solution and the colorimetric LAMP reaction mix._
### Table 1: Validated reagents used with the Test
| Item | Concentration | Chemical Composition | Vendor | Catalog Number |
|---|---|---|---|---|
| TCEP | .5 M | tris(2-carboxyethyl)phosphine hydrochloride | Sigma-Aldrich / Millipore Sigma | 646547-10X1ML |
| EDTA | .5 M | Ethylenediaminetetraacetic acid | Thermo Fisher | 15575020 |
| NaOH | 10 N | Sodium Hydroxide | Sigma-Aldrich | SX0607N-6 |
| Nuclease-free Water |  | Ultrapure Water, nuclease-free | Thermo Fisher | 10977015 |
| NaCl | 5 M | Sodium Chloride | Thermo Fisher | 24740011 |
| Guanidine HCl | 6 M | Guanidine Hydrochloride | Sigma-Aldrich | SRE0066 |
| Colorimetric LAMP MM* |  | Colorimetric LAMP Master Mix | New England Biolabs | M1804 |
||

### Table 2: Primer names and sequences
| Primer Name | Sequence (5’-3’) |
|---|---|
| **ORF1ab gene (AS1e)** |  |
| Orf1ab_FIP | TCAGCACACAAAGCCAAAAATTTATTTTTCTGTGCAAAGGAAATTAAGGAG |
| Orf1ab_BIP | TATTGGTGGAGCTAAACTTAAAGCCTTTTCTGTACAATCCCTTTGAGTG |
| Orf1ab_F3 | CGGTGGACAAATTGTCAC |
| Orf1ab_B3 | CTTCTCTGGATTTAAACACACTT |
| Orf1ab_LF | TTACAAGCTTAAAGAATGTCTGAACACT |
| Orf1ab_LB | TTGAATTTAGGTGAAACATTTGTCACG |
| **N Gene (N2)** |  |
| N2_FIP | TTCCGAAGAACGCTGAAGCGGAACTGATTACAAACATTGGCC |
| N2_BIP | CGCATTGGCATGGAAGTCACAATTTGATGGCACCTGTGTA |
| N2_F3 | ACCAGGAACTAATCAGACAAG |
| N2_B3 | GACTTGATCTTTGAAATTTGGATCT |
| N2_LF | GGGGGCAAATTGTGCAATTTG |
| N2_LB | CTTCGGGAACGTGGTTGACC |
||

### Table 7: Primer-Guanidine: Solution
| Component | Volume (1 reaction) | Volume (1 reaction x 100) 1 x 96-plate w/ 4% overage |
|---|---:|---:|
| 10X LAMP Primer Mix | 2.5 µL | 250 µL |
| Guanidine HCl (400 mM) | 2.5 µL |  |
| Guanidine HCl (6 M) |  | 16.7 µL |
| Nuclease-free Water | 5.5 µL | 783 µL |
| **TOTAL VOLUME** | **10.5 µL** | **1050 µL** |
||

### Table 8: Colorimetric LAMP Amplification Reaction
| Component | Volume (1 reaction) | Volume (100 reactions) |
|---|---:|---:|
| Primer–Guanidine Solution | 10.5 µL | 1050 µL |
| Colorimetric LAMP MM | 12.5 µL | 1250 µL |
| **SUBTOTAL VOLUME** | **23 µL** | **2300 µL** |
| Sample | 2 µL |  |
| **REACTION VOLUME** | **25 µL** |  |
||


## Slide 20: Push for Regulatory Progress
_Screenshot of Excerpt from PREVENT Pandemics Act legislation_
**Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act)**  

| Section | Topic | Key provisions |
|---|---|---|
| Sec. 505 | Facilitating the use of real world evidence | Requires FDA to issue or revise guidance on the use of real-world data and real-world evidence to support regulatory decisionmaking, including with respect to real-world data and real-world evidence from products authorized for emergency use. |
| Sec. 506 | Advanced platform technologies | Creates an advanced platform technology designation to expedite the development and review of new treatments and countermeasures that use cutting-edge, adaptable platform technologies that can be incorporated or used in more than one drug or biological product.<br><br>Requires FDA to issue guidance on the implementation of the new designation. |
| Sec. 507 | Increasing EUA decision transparency | Provides FDA with authority to share more safety and effectiveness information with the public about products authorized for emergency use. |
| Sec. 508 | Improving FDA guidance and communication | Requires publication of a report identifying best practices across the FDA and other applicable agencies for the development, issuance, and use of guidance documents and for communications with product sponsors and other stakeholders, and a plan for implementing such best practices.<br><br>Requires FDA to publish a report on the agency’s best practices for communicating with medical product sponsors and other stakeholders, and a plan for implementing such best practices. |
| Sec. 509 | GAO study and report on hiring challenges at FDA | Directs GAO to issue a report assessing FDA’s hiring, recruiting, and retention practices, policies, and processes, and their impact on FDA’s ability to carry out its public health mission, particularly in light of the COVID-19 pandemic. |
||

https://www.help.senate.gov/imo/media/doc/PREVENT%20Pandemics%20discussion%20draft%20sxs%20final.pdf

https://reaganudall.org/research-funding-opportunity


## Slide 21: LAMP EUAS for SARS-COV2
| EUA Date | Test | Diagnostic | Target | IC | Detection | Extraction | Amplification | LOD spike | LOD GE/3ml swab |
|---|---|---|---|---|---|---|---|---|---:|
| Nov-17 | Lucira (At Home POC) | Lucira COVID-19 All-In-One Test Kit | N, N | External + IC | Colorimetric | ~Direct | Lucira device | Inactivated virus | 2,700 |
| Oct-05 | Seasun (2 duplex) | AQ-TOP COVID-19 Rapid Detection Kit PLUS | orf1ab, N | Human RNaseP | PNA Probe | Manual (Qiagen_60704 or Seasun_SS-1300) or Automated (Panagene_PNAK-1001 on PanaMax48) | BioRad_CFX96 or ABI7500 | NCCP_43326 genomic RNA | 3000 |
| Sep-01 | Detectachem | MobileDetect Bio BCC19 (MD-Bio BCC19) Test Kit | N, E | only external controls | Colorimetric | Direct (1µl of transport media into LAMP) | heat block or qPCR (MD-Bio heater or BioRad_T100 or AB_Veriti or …) | Twist_MT007544.1 synthetic gRNA | 225,000 |
| Aug-31 | Mammoth | SARS-CoV-2 DETECTR Reagent Kit | N | Human RNaseP | CRISPR Probe | Automated (Qiagen_955134 on Qiagen_EZ1AdvancedBenchtop) | ABI7500 | SeraCare_AccuPlex_0505-0168 IVT encapsulated RNA | 60,000 |
| Aug-13 | Pro-Lab | Pro-AmpRT SARS-CoV-2 Test | RdRP | only external controls | Probe | Direct (swab into 0.1ml) or kit (swab into 1ml then Pro-lab_PLM-2000) | Optigene_GenieHT | BEI_NR-52287 inactivated virus | 125* |
| Jul-09 | UCSF/Mammoth | SARS-CoV-2 RNA DETECTR Assay | N | Human RNaseP | CRISPR Probe | automated (Qiagen_955134 on Qiagen_EZ1) | ABI7500 | SeraCare_AccuPlex_0505-0126 (lot 10480311) IVT RNA | 60,000 |
| May-21 | Seasun (1 duplex) | AQ-TOP COVID-19 Rapid Detection Kit | orf1ab | Human RNaseP | PNA Probe | manual (Qiagen_60704) | BioRad_CFX96 or ABI7500 | NCCP_43326 gRNA | 21,000 |
| May-18/Aug31 | Color | Color Genomics SARS-CoV-2 RT-LAMP Diagnostic Assay | N, E, nsp3 | Human RNaseP | Colorimetric | automated (PerkinElmer_CMG-1033 on PerkinElmer_Chemagic360) | plate reader (Biotek_NEO2), Hamilton_Star | ATCC_VR-1986D (gRNA) | 2,250 |
| May-06 | Sherlock BioSci | Sherlock CRISPR SARS-CoV-2 Kit | orf1ab, N | Human RNaseP | CRISPR Probe | Manual (ThermoFisher_12280050) | heat block or qPCR, Plate reader (BioTek_NEO2) | gRNA | 20,250 |
| Apr-10 | Atila BioSystems | iAMP COVID-19 Detection Kit | orf1ab, N | human GAPDH | Probe | Direct (swab into 350µl, 15min RT then 3µl to LAMP) | BioRad_CFX96 or ABI7500 or Roche_LightCycler480II or Atila_PG9600 | SeraCare_AccuPlex_0505-0129 pseudovirus (recombinant alphavirus) | 3,500* |
||

Just in 2020!
from Matt McFarlane
(twitter @mattmcfar)


## Slide 22: Saliva Direct most unique EUA" - FDA
_Screenshot of the SalivaDirect™ FDA EUA lab authorization request form, illustrating an open-protocol model where Yale can designate CLIA labs to run the assay._
- Is a protocol not a product
- Open Access - any CLIA can use
- Lots of clone assays being used

- Yale can "designate" CLIA labs

### SalivaDirect: Lab authorization request form
SalivaDirect received Emergency Use Authorization (EUA) from the Food and Drug
Administration (FDA) on August 15th, 2020.

The SalivaDirect FDA EUA is for a Laboratory Developed Test, but we have the right to designate other labs its use.

Only high complexity CLIA-certified labs in the United States C I become authorized to ru un SalivaDirect. Please fill out this form if you would like to receive more information on how to become a designated lab.

Do you have access to at least 5x SARS-COV-2 positive and 5x negative saliva samples for CLIA verification?*

Would you be open to collaboration on bridging studies for your automation
systems?


## Slide 23: Test Diagrams
### FloodLAMP QuickColor(TM) COVID-19 Test

```mermaid
graph TD
  A[Saline] --> B["1) INACTIVATION SOLUTION"]
  A2["100X Inactiv Solution<br/>TCEP/EDTA (standard Rabe Cepko)"] --> B
  B --> C[Pooled Dry Swab Samples]
  C --> D["Heat 95°C<br/>std: 8 min<br/>mini: 5 min"]
  D --> E["Let Cool<br/>std: 10 min<br/>mini: 5 min"]
  F["Primer Solution<br/>AS1e (ORF1ab)<br/>N2<br/>E1"] --> G["2) REACTION MIX"]
  F2["Color LAMP Master Mix<br/>NEB M1804"] --> G
  E --> H[Samples added to Reaction Mix]
  G --> H
  H --> I["Heat 65°C for 25 min"]

```


## Slide 24: Test Diagrams
### FloodLAMP QuickColor(TM) COVID-19 Test
_Diagram of detailed process flow with volumes and steps for preparing inactivation saline, inactivating pooled swabs, mixing reaction components, loading tubes/controls, and incubating to results._
```mermaid

flowchart LR
  %% -----------------------------
  %% Inactivation Saline Solution (left dashed box)
  %% -----------------------------
  subgraph ISS["Inactivation Saline Solution"]
    direction TB
    inact100x["100X<br/>Inactivation<br/>Solution"]
    saline[".9% Saline<br/>5,050 µL"]
    iss1x["1X Inactivation<br/>Saline Solution<br/>5,100 µL"]

    inact100x -->|50.5 µL| saline --> iss1x
  end

  %% -----------------------------
  %% Amplification Reaction Mix (top dashed box)
  %% -----------------------------
  subgraph ARM["Amplification Reaction Mix"]
    direction TB
    primer["Primer Solution<br/>(PGS)"]
    lampmm["Colorimetric LAMP<br/>MM (NEB M1804)<br/>8 reactions"]
    clampTube["1.5 mL Tube<br/>CLAMP<br/>Reaction Mix"]

    primer -->|92 µL| clampTube
    lampmm -->|110 µL| clampTube
  end

  %% -----------------------------
  %% Sample + Steps + Results
  %% -----------------------------
  pooled["Pooled Dry<br/>Swab Samples"]
  eluted["Eluted<br/>Sample<br/>1,000 µL"]

  heat95["Heat 95° C for<br/>8min<br/>STEP #1"]
  cool["Cool at<br/>Room Temp<br/>for 10min"]

  controls["Pos and Neg<br/>Controls"]

  strip["sample tubes"]

  heat65["Heat 65° C for<br/>25min<br/>STEP #2"]
  results{{"RESULTS!"}}

  iss1x -->|1,000 µL| pooled --> eluted --> heat95 --> cool

  clampTube -->|+ 23 µL Reaction Mix<br/>per tube| strip
  cool -->|+ 2 µL Sample| strip
  controls --> strip

  strip --> heat65 --> results
```


## Slide 25: Primer Comparison
_Bar charts comparing amplification time across three primer sets (A/N/E) and purification methods (HPLC vs desalted) at two input concentrations, showing faster performance for selected HPLC primers._
All 3 primer sets chosen by HPLC purification

Run with NEB E1700 Fluorimetric LAMP on QuantStudio7

Sample is contrived positive with Gamma BEI spiked into negative clinical sample

A = AS1e primer Rabe-Cepko set for ORFlab
N = N2 primer set
E = E1 primer set
"H" = HPLC purified
"D" = Desalted


## Slide 26: Successful Commercial Pilots
- Commercial deployments in 3 states.

- On-site, rapid mass molecular testing performed and operated by EMS staff.

2 cities have opted for mandatory FloodLAMP testing. Prioritizing it over antigen and PCR alternatives.

"FloodLAMP's testing program is a total game-changer. I didn't know this was possible. I've been blown away.
- President of Production Company for FloodLAMP Pilot program “ROSA”

"It's been a godsend!"
- EMS Training Director running the FloodLAMP program


## Slide 27: Town of Davie, FL
_Bar chart showing weekly screening volumes and positive results/positivity during the Omicron surge, with peaks in early 2022._


## Slide 28: Coral Springs, FL
_Bar chart showing weekly screening volumes and positive results/positivity with rapid increase in testing in early January 2022 and sustained high levels of testing through the end of February._


## Slide 29: Coral Springs, FL and Davie, FL
### Coral Springs, FL
_Photo collage of an on-site screening workspace and a PPE-clad tester, paired with a second photo of a Davie Fire Rescue room used for FloodLAMP COVID surveillance screening program operations._
A novice (but dedicated) tester is
able to screen 1000 critical city
employees.

### Davie, FL
_Photo of a small office/testing workspace at Davie Fire Rescue, with desks, supplies, and department insignia visible._


## Slide 30: Bend, OR
_Bar chart plotting week starting date (x-axis) versus number of people (y-axis), showing people screened with positives overlaid (percent positive labeled)_


## Slide 31: Preschool, CA
_Bar chart plotting week starting date (x-axis) versus number of people (y-axis), showing people screened with positives overlaid (percent positive labeled)_


## Slide 32: Pre-School Screening
_Photo of the Mon 1/10 preschool screening run, showing labeled sample tubes/plates and a mix of pooled versus individual specimens prepared for testing._
Mon 1-10

_Photo of the Thu 1/13 follow-up preschool screening run, showing additional self-collected individual and family-pool samples processed through the same workflow._
Thurs 1-13

Mix of self collected individuals and family pools


## Slide 33: Collaboration with University of Antioquia (Medellin, Colombia)
_Photo/map or logo slide highlighting collaboration with the University of Antioquia in Medellín, Colombia._
Joint NEB/FloodLAMP project


## Slide 34: Reagent Kits
_Photo collage of FloodLAMP reagent kit components (labeled tubes, assay reagents, and consumables) laid out for QuickColor™/EasyPCR™ workflows._


## Slide 35: Collection Kits
_Photo collage of participant collection kit materials (swabs, tubes/saline, labels, and packaging) used for pooled or individual sampling._


## Slide 36: Collection Instructions
_Photo of printed/graphic collection instructions showing how to swab, label, and package samples for submission._


## Slide 37: Training Program - Interactive Video
_Screenshot collage of the interactive training program (video modules with embedded questions using platform EdPuzzle) used to train and standardize operators._


## Slide 38: Training Program - Assessment for Certification
_Flowchart diagram of the certification pathway in Moodle/EdPuzzle, showing video modules, quizzes, pass/fail loops, practice runs, staff review, and final certification._
```mermaid
flowchart LR
  %% Unconnected reference box in the slide
  vlist["Video List for Phase1<br/>1) Overview<br/>2) Safety and Contamination<br/>3) Prep 1X ISS<br/>4) Prep Rxn Mix<br/>5) Inactivation<br/>6) Amplification (assay run)<br/>7) App and Resulting<br/>8) Dispenser"]

  start{{Send learner link to self-enroll}} --> login((Learner logs into Moodle))

  subgraph Moodle["Moodle Course<br/>Enrollment, completion, activity, etc data collection"]
    direction LR

    %% EdPuzzle sequence (use asymmetric shape to better match the screenshot blocks)
    ep1>EdPuzzle Interactive video w/ questions<br/>Create 1X Inactivation Solution]
    ep2>EdPuzzle Interactive video w/ questions<br/>Create Reaction Mix Solution]
    ep3>EdPuzzle Interactive video w/ questions<br/>Inactivation of Samples]
    ep4>EdPuzzle Interactive video w/ questions<br/>Amplification Run]
    ep5>EdPuzzle Interactive screencast w/ questions<br/>Review Amp Run Sheet]

    %% Quiz sequence (diamonds in the slide)
    reviewQuiz{"Review Quiz w Answers (moodle doc)"}
    takeQuiz{"Take Moodle Quiz (closed book)"}
    selfGradeQuiz{"Self Grade (logged in moodle)"}

    %% Pass/Fail nodes (rounded-corner boxes in the slide)
    passQuiz(Pass)
    failQuiz(Fail)

    requestPractice{"Request on-site Practice and cert"}
    recordRun["Record Run On site"]

    selfGradeOnsite{"Self Grade (logged in moodle)"}
    passOnsite(Pass)
    failOnsite(Fail)

    selfGradeOnsite -.->|Redo as needed| recordRun

    %% Double-border “assignment/subprocess” style box
    submitRun[[Submit self recorded full run to Moodle Assignment]]

    notify["Triggers FL Staff notification"]

    %% Trapezoid-ish staff review box (screenshot looks like reverse trapezoid)
    staffReview[\FloodLAMP Staff reviews video/]

    staffChecklist>"FloodLAMP Staff submits checklist on review of video"]

    passStaff(Pass)
    failStaff(Fail)

    cert{{"Certificate<br/>!!!"}}

    reviewSelected["Review Selected Videos"]

    %% Main flow
    login --> ep1 --> ep2 --> ep3 --> ep4 --> ep5 --> reviewQuiz --> takeQuiz --> selfGradeQuiz

    %% Quiz grading branches
    selfGradeQuiz --> passQuiz --> requestPractice --> recordRun --> selfGradeOnsite
    selfGradeQuiz -.-> failQuiz -.-> reviewSelected

    %% On-site self grade branches
    selfGradeOnsite --> passOnsite --> submitRun --> notify --> staffReview --> staffChecklist --> passStaff --> cert
    selfGradeOnsite --> failOnsite -.-> reviewSelected

    %% Staff checklist fail branch (dotted in slide)
    staffChecklist -.-> failStaff -.-> reviewSelected

    %% Remediation loop (dotted back to video set in slide)
    reviewSelected -.-> ep1
  end
```


## Slide 39: Quality Management System
_Screenshot collage of QMS forms and run sheets (with QR codes) illustrating ISO 13485-style documentation and log capture._
- Implementing ISO 13485 QMS
- QR Form Driven Logs


## Slide 40: New Site Validation Run
_Photo of a validation run layout with multiple labeled reaction tube strips, showing control and pool identifiers for a site validation check._
FloodLAMP Coral Springs Validation Run 8-2-21

Pool1
Pool2
Pool3
ZCP25
ZCP25
ZCP25
NC
TPC

GCP100
GCP100
GCP100
NC
FPNC
FPNC
FPNC
TPC


## Slide 41: Equipment and Supplies
_Photo collage of packed equipment and consumables in boxes and bins(pipettes, racks, heat blocks, PPE, and disposables) used to run FloodLAMP tests, illustrating the supplies shipped/organized for site setup._


## Slide 42: "Lab"
_Photo collage of a small “lab” room setup and a stocked supply cabinet used for on-site processing._


## Slide 43: Portable System
_Photo collage of a portable hard-case system and its organized contents (pipettes, racks, consumables) for deploying a testing site._


## Slide 44: Portable System -in action
_Photo collage of the portable system in a home use case, showing the pipettes, tubes, and heater on a kitchen counter._


## Slide 45: Prepared Cart
_Photo collage of a prepared drawer cart with labeled bins and close-ups of organized consumables (tips, tubes, racks) ready for rapid setup and ease of use in processing._


## Slide 46: Clinical Evaluation Data
Clinical evaluation performed by the Stanford CLIA Lab, with excellent results and praise on the "really straightforward" protocol.

### EasyPCR(TM) Test
- 3 copies/µl LoD
- 98% sensitivity (PPA 39/40)
- 100% Specificity (40/40)
- No false positives

### QuickColor(TM)  LAMP Test
- 12 copies/µl LoD
- 90% Sensitivity (PPA 36/40)
- Missed positives only high Ct (>36 with direct PCR)
- 100% Specificity (40/40)
- No false positives

_Scatter plot of FloodLAMP EasyPCR(TM) preliminary LoD showing Ct (y-axis) versus target concentration in copies/mL (x-axis), with Ct decreasing from ~37 to ~32 as copies/mL increases up to 100,000._
Gamma inactivated cell lysate from BEI spiked into raw clinical negative sample

| FloodLAMP SwabDirect PCR Result | Comparator Positive | Comparator Negative | Total |
|---|---:|---:|---:|
| Positive | 39 | 0 | 39 |
| Negative | 1 | 40 | 41 |
| Invalid | 0 | 0 | 0 |
| **Total** | **40** | **40** | **80** |
||

- Positive Agreement: **97.5% (39/40)**; 95% CI: **86.8% to 99.9%**
- Negative Agreement: **100% (40/40)**; 95% CI: **91.2% to 100%**


| FloodLAMP QuickColor Test Result | Comparator Positive | Comparator Negative | Total |
|---|---:|---:|---:|
| Positive | 36 | 0 | 36 |
| Negative | 4 | 40 | 44 |
| **Total** | **40** | **40** | **80** |
||

- Positive Agreement: **90.0% (36/40)**; 95% CI: **76.3% to 97.2%**
- Negative Agreement: **100% (40/40)**; 95% CI: **91.2% to 100%**

Source of Specimens: Stanford COVID-19 Clinical Testing Program
Specimen Type: Anterior Nares Swab in PBS, previously tested and frozen
Comparator Test: Hologic Panther Fusion SARS-CoV-2 Assay and Hologic Panther Aptima SARS-CoV-2 Assay


## Slide 47: Clinical Evaluation by Stanford CLIA Lab
_Screenshot/photo from the Stanford CLIA Lab evaluation microtiter wellplate of LAMP reactions._


## Slide 48: Clinical Evaluation by Stanford CLIA Lab
_Bar chart of Stanford CLIA QuickColor™ evaluation outcomes for 40 positive and 40 negative samples, showing positives, inconclusives (high Ct/low viral load), and negatives among true positives and zero false positives in true negatives._
### 40 Clinical Positive Samples:
29 Positive by FloodLAMP QuickColor(TM) Test
  7 Inconclusive (all high Ct, low viral load)
  4 Negative (all > 36 Ct, very low viral load)

### 40 Clinical Negative Samples:
40 Negative by FloodLAMP QuickColor(TM) Test


## Slide 49: Clinical Evaluation by Stanford CLIA Lab
### Clinical Evaluation: 40 SARS-CoV2 Positive Remnant Samples
_Scatter Plot with Direct PCR (FloodLAMP EasyPCR) thawed after 2 months Ct values (y-axis) vs (Comparator Purified PCR (Hologic Fusion) original fresh sample Ct values (x-axis)_
One sample Undetermined (not detected) by FloodLAMP(TM) EasyPCR

Detected in FloodLAMP EasyPCR(TM)
Not detected by FloodLAMP QuickColor(TM) 
(EasyPCR(TM) PPA   39/40  97.5%)

Detected in both FloodLAMP EasyPCR(TM) and  QuickColor(TM) Colorimetric LAMP test
(QuickColor(TM) PPA   36/40   90%)
* includes initial inconclusive resolved by PCR

Both FloodLAMP EasyPCR(TM) and  QuickColor(TM) had no false positives
(NPA   40/40  100%)


## Slide 50: Clinical Evaluation by Stanford CLIA Lab
### FloodLAMP Stanford Clinical Evaluation - All 3 Tests: Fluorimetric LAMP, Colorimetric LAMP, and PCR
_Scatter Plot with FloodLAMP QuickFluor LAMP Ct (minutes) vs FloodLAMP EasyPCR Ct_
One sample not detected by
FloodLAMP EasyPCR(TM)
(PPA 39/40 97.5%)

6 Positives Not Detected by
FloodLAMP QuickFluor(TM) test
(PPA 34/40 85%)

Positives detected not by
FloodLAMP QuickColor(TM) test
(PPA 36/40 90%)
* includes initial inconclusives resolved by
PCR

All 3 Tests:
No false positives
- FloodLAMP EasyPCR(TM)
- QuickColor(TM) LAMP
- QuickFluor(TM) LAMP
(NPA 40/40 100%)


## Slide 51: Antigen Tests Headlines and Paper
_Screenshot collage of a news article and medRxiv preprint excerpt summarizing rapid antigen test performance for Omicron versus Delta in asymptomatic serial self-testing._

HEALTH
Several common rapid antigen tests work well for Omicron, according to a new study.
The new findings are from an ongoing U.S. study that began in October and was designed to assess the performance of rapid antigen tests in asymptomatic people.
By Emily Anthes
March 1, 2022

medRxiv
THE PREPRINT SERVER FOR HEALTH SCIENCES
CSH (Cold Spring Harbor Laboratory) • BMJ • Yale

Comparison of Rapid Antigen Tests’ Performance between Delta (B.1.617.2;AY.X) and Omicron (B.1.1.529;BA.1) Variants of SARS-CoV-2: Secondary Analysis from a Serial Home Self-Testing Study
Apurv Soni; Carly Herbert; Andreas Filippaios; John Broach; Andres Colubri; Nisha Fahey; Kelsey Woods; Janvi Nanavati; Colton Wright; Taylor Orwig; Karen Gilliam; Vik Kheterpal; Tejas Suvarna; Chris Nowak; Summer Schrader; Honghuang Lin; Laurel O’Connor; Caitlin Pretz; Didem Ayturk; Elizabeth Orvek; Julie Flahive; Peter Lazar; Qiming Shi; Chad Achenbach; Robert Murphy; Matthew Robinson; Laura Gibson; Pamela Stamegna; Nathaniel Hafer; Katherine Luzuriaga; Bruce Barton; William Heetderks; Yukari C. Manabe; David McManus
doi: https://doi.org/10.1101/2022.02.27.22271090

Results From the 7,349 participants enrolled in the parent study, 5,506 met the eligibility criteria for this analysis. **A total of 153 participants were RT-PCR+ (61 Delta, 92 Omicron); among this group, 36 (23.5%) tested Ag-RDT+ on the same day and 36 (23.5%) tested Ag-RDT+ within 48 hours as first RT-PCR+.** The differences in sensitivity between variants were not statistically significant (same-day: Delta 16.4% [95% CI: 8.2-28.1] vs Omicron 28.2% [95% CI: 19.4-38.6]; and 48-hours: Delta 45.9% [33.1-59.2] vs.


## Slide 52: App
For program participants
_Screenshot collage of the participant-facing mobile app showing registration/check-in, sample accessioning (e.g., QR codes), and result notifications._


## Slide 53: App
For the lab
_Screenshot collage of the lab-facing app workflow for scanning samples, tracking runs, and recording/reporting results._


## Slide 54: Admin portal
Tools for program administrators
_Screenshot of the admin portal dashboard used by program administrators to manage participants, sites, and testing/reporting logistics._


## Slide 55: Team Effort!
_Photo collage of lab staff at benches and close-up shots of personnel in PPE performing sample handling and labeling tasks._